The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.
The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.
In life sciences companies, collaboration is key. It’s important for operational leaders to partner with finance leaders to consider risks and issues that may…
Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.
Around a third of Trevena’s workforce are facing the ax as the biotech throws all its weight behind soon-to-be-filed injectable pain therapy Olinvo.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Ardelyx now has a second positive phase 3 trial for its constipation-predominant irritable bowel syndrome drug tenapanor.
Just months after its $80 million IPO, AnaptysBio is looking to raise another block of cash and accelerate development of its lead drug for eczema.
The $12.8 million equips the team to expand arms that are assessing different routes of administration of the IL13Rα2‐specific autologous CAR-T cells.
Sarepta is hoping to avoid the data-quality controversy that arose over its Duchenne muscular dystrophy drug Exondys51 last year with its next-generation drug…
The move sees Saha end his near-10-year spell away from Big Pharma for the chance to run Bristol-Myers’ translational medicine operation.
PanOptica plans to start trialling the small molecule anti-vascular endothelial growth factor eye drop early next year.